{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T01:39:43Z","timestamp":1789781983145,"version":"4.0.1"},"reference-count":34,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.3892\/or.2015.4058","type":"journal-article","created":{"date-parts":[[2015,6,12]],"date-time":"2015-06-12T06:56:22Z","timestamp":1434092182000},"page":"633-638","source":"Crossref","is-referenced-by-count":7,"title":["Combinatorial anti-angiogenic gene therapy in a human malignant mesothelioma model"],"prefix":"10.3892","volume":"34","author":[{"given":"SHUJI","family":"KUBO","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MISATO","family":"TAKAGI-KIMURA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NORIYUKI","family":"KASAHARA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2015,6,12]]},"reference":[{"key":"key20180107212255_b1-or-34-02-0633","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/107327480601300402","article-title":"Malignant pleural mesothelioma: A comprehensive review","volume":"13","author":"Ismail-Khan","year":"2006","journal-title":"Cancer Control"},{"key":"key20180107212255_b2-or-34-02-0633","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1200\/JCO.2008.19.8523","article-title":"Malignant pleural mesothelioma","volume":"27","author":"Tsao","year":"2009","journal-title":"J Clin Oncol"},{"key":"key20180107212255_b3-or-34-02-0633","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/sj.cgt.7700935","article-title":"Gene therapy for malignant mesothelioma: Beyond the infant years","volume":"13","author":"van der Most","year":"2006","journal-title":"Cancer Gene Ther"},{"key":"key20180107212255_b4-or-34-02-0633","first-page":"51","article-title":"New and emerging therapeutic options for malignant pleural mesothelioma: Review of early clinical trials","volume":"7","author":"Kotova","year":"2015","journal-title":"Cancer Manag Res"},{"key":"key20180107212255_b5-or-34-02-0633","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/nm.2537","article-title":"Tumor angiogenesis: Molecular pathways and therapeutic targets","volume":"17","author":"Weis","year":"2011","journal-title":"Nat Med"},{"key":"key20180107212255_b6-or-34-02-0633","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000025623","article-title":"Angiostatin diminishes activation of the mitogen-activated protein kinases ERK-1 and ERK-2 in human dermal microvascular endothelial cells","volume":"36","author":"Redlitz","year":"1999","journal-title":"J Vasc Res"},{"key":"key20180107212255_b7-or-34-02-0633","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0092-8674(94)90200-3","article-title":"Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma","volume":"79","author":"O\u2019reilly","year":"1994","journal-title":"Cell"},{"key":"key20180107212255_b8-or-34-02-0633","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/sj.cgt.7700388","article-title":"Development of lentiviral vectors for antiangiogenic gene delivery","volume":"8","author":"Shichinohe","year":"2001","journal-title":"Cancer Gene Ther"},{"key":"key20180107212255_b9-or-34-02-0633","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0092-8674(00)81848-6","article-title":"Endostatin: An endogenous inhibitor of angiogenesis and tumor growth","volume":"88","author":"O\u2019reilly","year":"1997","journal-title":"Cell"},{"key":"key20180107212255_b10-or-34-02-0633","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.1073\/pnas.081615298","article-title":"Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer","volume":"98","author":"Kuo","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180107212255_b11-or-34-02-0633","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3171\/JNS\/2008\/108\/5\/0979","article-title":"Successful inhibition of intracranial human glioblastoma multiforme xenograft growth via systemic adenoviral delivery of soluble endostatin and soluble vascular endothelial growth factor receptor-2: Laboratory investigation","volume":"108","author":"Szentirmai","year":"2008","journal-title":"J Neurosurg"},{"key":"key20180107212255_b12-or-34-02-0633","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1089\/hum.2006.17.941","article-title":"Inhibition of ovarian tumor growth by gene therapy with recombinant soluble vascular endothelial growth factor receptor 2","volume":"17","author":"Wu","year":"2006","journal-title":"Hum Gene Ther"},{"key":"key20180107212255_b13-or-34-02-0633","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ctrv.2011.01.001","article-title":"Advances in the biology of malignant pleural mesothelioma","volume":"37","author":"Zucali","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"key20180107212255_b14-or-34-02-0633","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ctrv.2012.12.005","article-title":"Malignant mesothelioma: New insights into a rare disease","volume":"39","author":"Remon","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"key20180107212255_b15-or-34-02-0633","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/path.824","article-title":"Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma","volume":"193","author":"Strizzi","year":"2001","journal-title":"J Pathol"},{"key":"key20180107212255_b16-or-34-02-0633","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<72::AID-PATH401>3.0.CO;2-0","article-title":"Angiogenic cytokines in mesothelioma: A study of VEGF, FGF-1 and -2, and TGF beta expression","volume":"189","author":"Kumar-Singh","year":"1999","journal-title":"J Pathol"},{"key":"key20180107212255_b17-or-34-02-0633","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/JTO.0b013e3181d2f008","article-title":"Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma","volume":"5","author":"Yasumitsu","year":"2010","journal-title":"J Thorac Oncol"},{"key":"key20180107212255_b18-or-34-02-0633","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/j.clinthera.2007.09.008","article-title":"Ranibizumab for the treatment of neovascular age-related macular degeneration: A review","volume":"29","author":"Kourlas","year":"2007","journal-title":"Clin Ther"},{"key":"key20180107212255_b19-or-34-02-0633","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1517\/14712590902817817","article-title":"Bevacizumab: Current indications and future development for management of solid tumors","volume":"9","author":"Jenab-Wolcott","year":"2009","journal-title":"Expert Opin Biol Ther"},{"key":"key20180107212255_b20-or-34-02-0633","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3816\/CLC.2010.n.011","article-title":"The role of anti-epidermal growth factor receptor and anti-vascular endothelial growth factor therapies in the treatment of non-small-cell lung cancer","volume":"11","author":"Langer","year":"2010","journal-title":"Clin Lung Cancer"},{"key":"key20180107212255_b21-or-34-02-0633","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/bjc.2013.368","article-title":"Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma","volume":"109","author":"Ceresoli","year":"2013","journal-title":"Br J Cancer"},{"key":"key20180107212255_b22-or-34-02-0633","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.lungcan.2012.05.111","article-title":"A multicenter phase ii study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma","volume":"77","author":"Dowell","year":"2012","journal-title":"Lung Cancer"},{"key":"key20180107212255_b23-or-34-02-0633","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1128\/JVI.77.5.2964-2971.2003","article-title":"A new hybrid system capable of efficient lentiviral vector production and stable gene transfer mediated by a single helper-dependent adenoviral vector","volume":"77","author":"Kubo","year":"2003","journal-title":"J Virol"},{"key":"key20180107212255_b24-or-34-02-0633","doi-asserted-by":"crossref","first-page":"8036","DOI":"10.1073\/pnas.0601954103","article-title":"L1 retrotransposition in non-dividing and primary human somatic cells","volume":"103","author":"Kubo","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180107212255_b25-or-34-02-0633","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1248\/bpb.34.1785","article-title":"Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy","volume":"34","author":"Takahashi","year":"2011","journal-title":"Biol Pharm Bull"},{"key":"key20180107212255_b26-or-34-02-0633","doi-asserted-by":"crossref","first-page":"5547","DOI":"10.1182\/blood-2009-04-217380","article-title":"EMMPRIN promotes angiogenesis through hypoxia-inducible factor-2alpha-mediated regulation of soluble VEGF isoforms and their receptor VEGFR-2","volume":"114","author":"Bougatef","year":"2009","journal-title":"Blood"},{"key":"key20180107212255_b27-or-34-02-0633","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.cell.2007.06.054","article-title":"Autocrine VEGF signaling is required for vascular homeostasis","volume":"130","author":"Lee","year":"2007","journal-title":"Cell"},{"key":"key20180107212255_b28-or-34-02-0633","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1242\/jcs.114.5.853","article-title":"The splice variants of vascular endothelial growth factor (VEGF) and their receptors","volume":"114","author":"Robinson","year":"2001","journal-title":"J Cell Sci"},{"key":"key20180107212255_b29-or-34-02-0633","doi-asserted-by":"crossref","first-page":"5918","DOI":"10.1158\/1078-0432.CCR-07-0501","article-title":"The therapeutic efficacy of anti vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice","volume":"13","author":"Li","year":"2007","journal-title":"Clin Cancer Res"},{"key":"key20180107212255_b30-or-34-02-0633","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/cgt.2011.25","article-title":"Replication-competent retrovirus vector-mediated prodrug activator gene therapy in experimental models of human malignant mesothelioma","volume":"18","author":"Kawasaki","year":"2011","journal-title":"Cancer Gene Ther"},{"key":"key20180107212255_b31-or-34-02-0633","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/cgt.2013.67","article-title":"Highly efficient tumor transduction and antitumor efficacy in experimental human malignant mesothelioma using replicating gibbon ape leukemia virus","volume":"20","author":"Kubo","year":"2013","journal-title":"Cancer Gene Ther"},{"key":"key20180107212255_b32-or-34-02-0633","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/jgm.1486","article-title":"Complete regression of human malignant mesothelioma xenografts following local injection of midkine promoter-driven oncolytic adenovirus","volume":"12","author":"Kubo","year":"2010","journal-title":"J Gene Med"},{"key":"key20180107212255_b33-or-34-02-0633","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/cgt.2014.7","article-title":"Oncolytic virotherapy for osteosarcoma using midkine promoter-regulated adenoviruses","volume":"21","author":"Takagi-Kimura","year":"2014","journal-title":"Cancer Gene Ther"},{"key":"key20180107212255_b34-or-34-02-0633","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1111\/cas.12267","article-title":"Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma","volume":"104","author":"Takagi-Kimura","year":"2013","journal-title":"Cancer Sci"}],"container-title":["Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/or.2015.4058\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T13:27:44Z","timestamp":1717939664000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/or.2015.4058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,12]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2015,6,12]]},"published-print":{"date-parts":[[2015,8]]}},"alternative-id":["10.3892\/or.2015.4058"],"URL":"https:\/\/doi.org\/10.3892\/or.2015.4058","relation":{},"ISSN":["1021-335X","1791-2431"],"issn-type":[{"value":"1021-335X","type":"print"},{"value":"1791-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,12]]}}}